Introduction
Genomic DNA in the nucleus is packaged into the nucleosome, which consists of an octamer of histones (two of each H2A, H2B, H3, and H4) wrapped around with 146bp genomic DNA. 1 The amino-terminal tails of the core histones can be modified by posttranslational modifications such as lysine (K) methylation (me), which is mediated by histone methyltransferases (HMTs). 2 The suppressor of variegation, enhancer of zeste, trithorax (SET) domain was first recognized as a conserved feature in chromatin-associated proteins 3, 4 and a number of SET domain-containing proteins have since been characterized as HMTs. 5, 6 For example, SUV39H1, SUV39H2, and SET9 methylate H3 or H4 and function as important epigenetic regulators of mammalian development, heterochromatin, and genomic instability. 7, 8 Deregulation of SET-domain function has an important role in carcinogenesis. 9, 10 Mixedlineage leukemia 1 (MLL1) is one of the best studied SET domain-containing proteins in human cancer, which is disrupted by chromosomal translocations resulting in the aberrant expression of chimeric proteins. 11 Notably, all the fusion products contain the N-terminal 1400 amino acids of MLL1 and lack the SET domain. 11 In addition, a common feature of SET domain-containing proteins is that their full length proteins such as RIZ1, MDS1-EVI1 and MMSET-II appear to act as tumor suppressors, while the corresponding SET domainlacking proteins, RIZ2, EVI1, and MMSET-I, function as oncogenes. 9, 12 Truncation of the full length protein can be caused by either translocations or alternative splicing. 12 V(D)J recombination is a site-specific DNA recombination process 13 which breaks and rejoins DNA segments of antigen receptor loci in lymphocyte progenitors. 13 DNA double strand breaks (DSBs) generated during V(D)J recombination are repaired by non-homologous end-joining (NHEJ). XRCC4 is an essential co-factor of DNA ligase IV (Lig4) and co-operates with Lig4 to catalyze the ligation step of NHEJ.
14 We previously inactivated Xrcc4 specifically in peripheral B cells.
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Xrcc4 conditional knockout mice are not cancer-prone; however, once bred into a p53 deficient background, they often succumb to B-lineage lymphomas (termed CXP lymphomas) that frequently harbor clonal translocations. 16 In this study, we present a SET domain-containing protein, SETD3, which is involved in a translocation to the immunoglobulin lambda (Igλ) light chain locus in one of the CXP lymphomas.
Design and Methods

Cytogenetic assays, SKY, FISH and chromosomal painting
Preparation of metaphase chromosomes, spectral karyotyping (SKY), fluorescence in situ hybridization (FISH), and whole-chromosome painting using single-chromosome-specific paints were performed as previously described. 16 FISH probes were as follows: BACs for Setd3 on chr12 are RP23-360E20, RP23-42A17, and RP23-32G7 obtained from the BACPAC CHORI database.
Further details of Design and Methods are available in the Online Supplementary Appendix.
Results and Discussion
Identification of Setd3 from a NHEJ/p53-deficient peripheral B cell lymphoma
We initially observed a t(12;16) translocation by SKY in the CXP163 tumor (Online Supplementary Figure S1 ). 16 Next, we attempted to map the junction of this translocation by FISH. Cytogenetic analysis using bacterial artificial chromosomes Figure 1B ). To clarify the nature of these Igλ rearrangements, we cloned them from genomic phage libraries generated from CXP163 tumor DNA. Molecular cloning revealed the translocation breakpoint that fused a portion of the Setd3 gene into the Jλ1-Cλ1 region containing the 3'Igλ enhancer ( Figure 1C ). The translocation junction occurred within intron 8 of Setd3 and fused Setd3 exons 9 through 13 to the intronic sequences just upstream of the Jλ1-Cλ1 region in a headto-head configuration ( Figure 1C and D) . In this configuration, sense strands of these two genes are in opposite ori-
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haematologica | 2013; 98(5) Figure 1 . 16 These studies eventually showed that CXP lymphomas arose from peripheral B cells that had attempted secondary V(D)J recombination of Igκ and Igλ light chain genes. Correspondingly, CXP tumors frequently harbored large chromosomal deletions or translocations involving Igκ or Igλ. 16 The t(12;16) translocation in the CXP163 lymphoma is not a balanced translocation, and the remainder of the distal portion of Chr12 was lost, as shown by SKY (Online Supplementary Figure S1) . Notably, the genomic configuration of the region surrounding Setd3 on mouse Chr12 is highly conserved with human Chr14q32.2, a critical region frequently involved in lymphomagenesis. 17 Thus, it is likely that there is a potential oncogenic consequence of the distal 12q deletion caused by the t(12;16) translocation.
Characterization of the Setd3 gene in tumor and normal tissues
The mouse Setd3 gene is normally located on the telomeric end of Chr12 containing 13 exons (Online Supplementary Figure S2A ). This Igλ translocation disrupted the Setd3 gene, and the breakpoint occurred in intron 8, which is 1897bp upstream of exon 9. Using Northern blot analysis, we identified a truncated Setd3 transcript (designated as Setd3-S) which accumulated to a much higher steady state level in CXP163 than the full length Setd3 transcript (designated as Setd3-L) in wild-type (wt) splenic B cells or in other CXP tumors lacking this translocation ( Figure 1E) . Presumably, the putative promoter that drives the expression of Setd3-S is located within the 1897bp upstream of exon 9 of Setd3. In addition, the 3'Igλ enhancer in close vicinity might also contribute to the high expression of Setd3-S transcript. Next, we cloned the cDNA of Setd3-S using primers specific to the 5' end of exon 9 and 3' end of exon 13. This particular cDNA contains an open reading frame with the start codon (ATG) located within exon 10. Thus, we concluded that this Igλ translocation led to the production of a truncated Setd3 transcript encoding the C-terminal portion of Setd3.
Lack of further material precluded the characterization of SETD3 protein in CXP163. To investigate whether both Setd3 transcripts encode proteins with proper size, a Flagtag was added to the C-terminal end of the Setd3-L and Setd3-S cDNAs. Cell extracts from Setd3-L, Setd3-S, or control vector transfected 293T cells were employed for Western blot analysis to detect the SETD3 proteins. Our SETd3-L SETd3-S Transfectants ***P=5.76x10 data confirmed that Setd3-L and Setd3-S cDNAs gave rise to proteins with the predicted size, about 67kd and 30kd, respectively ( Figure 1F ). There are multiple variants of Setd3 transcripts identified in the database (see Online Supplementary Appendix) which are generated via alternative splicing.
We next examined the Setd3 transcript in various tissues by Northern blot and found that the Setd3-L transcript was present ubiquitously in all the tissues tested using the GAPDH transcript as control (Online Supplementary Figure  S2B and C) . The Setd3 gene encodes a protein with a highly conserved SET domain located at the N-terminus and a well-conserved RuBisCo lysine methyltransferase (LSMT) C-terminal substrate-binding domain (Online Supplementary Figure S3) . Interestingly, the truncated SETD3-S protein lacks the highly conserved SET domain. The human homolog of SETD3 protein is 92% identical to its mouse counterpart (NCBI_Blastp). Thus, the Igλ translocation revealed a novel SET domain-containing protein, SETD3, which was also recently identified by independent studies using a bioinformatics approach.
18,19
Role of Setd3 in cell growth
Since the expression of the truncated Setd3-S transcript was much greater in the CXP163 tumor, we next tested whether SETD3-S has oncogenic potential using a soft agar assay. Normally, NIH3T3 cells can not undergo anchorage independent growth and do not form colonies in soft agar. To test whether SETD3-S or SETD3-L can induce colony formation of NIH3T3 cells, we infected these cells with retroviruses expressing either Setd3-S or Setd3-L cDNA with a Flag-tag at the C-terminal end, or empty vector as a negative control. These analyses revealed that the cells infected with Setd3-S can form colonies at a much higher level compared to cells infected with empty vector or uninfected cells (Figure 2A and B) . In contrast, the colony number in the Setd3-L infected group was similar to that in control groups (Figure 2A and B) . The cells infected with retrovirus expressing Ras V12 with a C-terminal HA-tag served as a positive control that induced robust colony formation of 3T3 cells (Figure 2A and B). Western blot analysis showed the expression of corresponding exogenous proteins in the different groups of infected cells (Figure 2A) . Thus, we conclude that the truncated SETD3-S has an oncogenic potential to transform NIH3T3 cells, whereas the full length SETD3-L does not. Our data also suggest that the highly expressed Setd3-S in CXP163 might contribute to lymphomagenesis. In this context, the CXP163 lymphoma not only highly expresses truncated Setd3-S transcript ( Figure 1E ) but also dramatically up-regulates expression of the c-myc oncogene 16 which is due to a t(12;15) translocation (Online Supplementary Figure S1 ) juxtaposing the c-myc oncogene next to the 3'Igh regulatory region. 16 Thus, we reasoned that the truncated Setd3-S, possibly by disrupting Setd3-L function, might co-operate with c-myc to promote oncogenesis. Next, we tested whether co-expression of c-myc and Setd3-S in primary mouse embryonic fibroblasts (MEFs) promotes colony formation. Primary MEFs were infected with retroviruses expressing Setd3-S, Setd3-L as described above, or c-myc with a C-terminal HA-tag, or empty vector. Western blot analysis showed the expression of exogenous proteins in the corresponding groups of infected 3T3 cells ( Figure 2C ). Our data showed that cmyc expression had a moderate effect on colony formation of primary MEFs, whereas both Setd3-S and Setd3-L had no obvious effects compared to the control group ( Figure 2C ). In contrast, when c-myc and Setd3-S were coexpressed, the number of colonies was significantly increased, whereas co-expression of Setd3-L with c-myc had no such effects ( Figure 2C ). Thus, our data demonstrate that Setd3-S may have the potential to function as an oncogene.
Functions of SETD3 in histone modification
To investigate whether SETD3 has any SET domaindependent enzymatic activity on histones, we performed in vitro HMT activity assays. First, we expressed and purified recombinant Glutathione S-transferase (GST) only, GST-SETD3-L, and GST-SETD3-S proteins ( Figure 3A) . These purified proteins were assayed for their putative methyltransferase activity using native HeLa nucleosomes, containing all histones except H1, as substrates. 20 We found that only the purified GST-SETD3-L protein showed robust H3-specific HMT activities on the substrates ( Figure 3B ). In contrast, GST-SETD3-S or GST proteins displayed no detectable level of HMT activity ( Figure  3B ). When free histone octamers were used as substrates, we could not detect any HMT activity (data not shown), suggesting that SETD3-L only functions on the physiologically relevant substrates, i.e. native nucleosomes, of which H3 is a component. Thus, we conclude that the SETD3 protein is a fully active HMT for H3 with its activity dependent on the SET domain. Recently, independent studies also identified the zebrafish and mouse Setd3 genes via a bioinformatics approach 18, 19 which also haematologica | 2013; 98(5) showed that SETD3 has HMT activity, in particular, on H3K4 and H3K36. 18 These studies used several H3 peptides instead of nucleosomes as substrates for the HMT assay. However, we could not detect HMT activity when free histone octamers were employed as substrates. It is likely that the activity of SETD3 on native nucleosomes, which are physiological substrates in vivo, is higher than that on free histone substrates. It remains to be determined whether SETD3 displays the same substrate specificity on native nucleosomes. In addition, SETD3 contains another well-conserved RuBisCo LSMT C-terminal substrate-binding domain. Rubisco LSMT is a chloroplast-localized SET domain-containing protein, which catalyzes the trimethylation of K14 in the large subunit of Rubisco, 21 an essential photosynthetic enzyme. 22 The RuBisCo LSMT C-terminal substrate-binding domain is also present in ribosomal lysine (K) methyltransferase (RKM) 1-4 of Saccharomyces cerevisiae.
23 RKM1 has been shown to methylate the ribosomal 23 subunit. 24 Thus, it remains possible that SETD3 might also have other non-histone substrates in the cytoplasm. Taken together, we propose that SETD3-L might function through its well-conserved SET domain and play an important role in suppressing tumor development while SETD3-S might function as a dominant negative mutant of SETD3-L and promote oncogenesis. Thus, it would be of interest to investigate the potential involvement of the Setd3 gene in carcinogenesis.
